Product Portfolio

Marketed Therapies

Below is a list of our company's marketed products. This information is intended only for residents of Australia.

 

 

AVONEX® (interferon beta-1a)

Registered in Australia in October 1999.

For patients:  Consumer Medicine Information (CMI)
For healthcare professionals:  Product Information (PI)

FAMPYRA® (fampridine)

Registered in Australia in May 2011.

For patients:  Consumer Medicine Information (CMI)

For healthcare professionals: Product Information (PI)

PLEGRIDY™ (peginterferon beta-1a)

Registered in Australia in November 2014.

For patients:  Consumer Medicine Information (CMI)

For healthcare professionals: Product Information (PI)

SPINRAZA™ (nusinersen)

Registered in Australia in November 2017.

For patients:  Consumer Medicine Information (CMI)

For healthcare professionals: Product Information (PI)

TECFIDERA® (dimethyl fumarate)

Registered in Australia in July 2013.

For patients:  Consumer Medicine Information (CMI)

For healthcare professionals: Product Information (PI)

TYSABRI® (natalizumab)

Registered in Australia in November 2006.

For patients:  Consumer Medicine Information (CMI)

For healthcare professionals: Product Information (PI)